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In Brief
Hypoxia, via activation of HIF-1, is known
to inhibit fatty acid oxidation (FAO) as part
of the metabolic reprogramming of can-
cer cells, but the mechanisms linking
FAO and cancer progression are unclear.
Huang et al. now report that HIF-1 inhibi-
tion of two FAO enzymes, the acyl-CoA
dehydrogenases MCAD and LCAD, pro-
motes cancer progression via effects on
ROS and glycolysis and that LCAD loss
further promotes cancer by regulating
the PTENpathway, highlighting the signif-
icance of FAO inhibition in cancer.
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Hypoxia-inducible factor 1 (HIF-1) mediates a meta-
bolic switch that blocks the conversion of pyruvate
to acetyl-CoA in cancer cells. Here, we report that
HIF-1a also inhibits fatty acid b-oxidation (FAO),
another major source of acetyl-CoA. We identified a
PGC-1b-mediated pathway by which HIF-1 inhibits
the medium- and long-chain acyl-CoA dehydroge-
nases (MCAD and LCAD), resulting in decreased
reactive oxygen species levels and enhanced pro-
liferation. Surprisingly, we further uncovered that
blocking LCAD, but not MCAD, blunts PTEN expres-
sion and dramatically affects tumor growth in vivo.
Analysis of 158 liver cancer samples showed that
decreased LCAD expression predicts patient mortal-
ity. Altogether, we have identified a previously unap-
preciated mechanism by which HIF-1 suppresses
FAO to facilitate cancer progression.INTRODUCTION
The reprogramming of cellular energy metabolism is one of the
recognized ‘‘emerging hallmarks’’ of human cancer (Hanahan
and Weinberg, 2011). Warburg first observed that compared to
normal cells, cancer cells have increased conversion of glucose
to lactate (Vander Heiden et al., 2009). Because metabolism is a
fundamental activity that determines cellular fate, tremendous
effort has been made in the past 2 decades to understand the
molecular mechanisms underlying its reprogramming in cancer
cells (DeBerardinis and Thompson, 2012). For instance, hypox-
ia-inducible factor 1 (HIF-1) mediates a metabolic switch that
shunts glucose metabolites away from the mitochondria (Kim
et al., 2006). HIF-1 regulates the expression of pyruvate dehy-
drogenase kinase 1, which inactivates pyruvate dehydrogenase,
the enzyme that catalyzes the conversion of pyruvate to acetyl-
CoA for entry into the tricarboxylic acid (TCA) cycle. Mitochon-1930 Cell Reports 8, 1930–1942, September 25, 2014 ª2014 The Audrial respiration under prolonged hypoxic conditions results in
increased generation of reactive oxygen species (ROS) and
cell death (Kim et al., 2006). Hence, metabolic reprogramming
to limit acetyl-CoA generation and TCA cycle activity is an adap-
tive strategy for cells in the hypoxic microenvironment that is
characteristic of advanced cancers. However, whereas acetyl-
CoA is also generated by fatty acid b-oxidation (FAO), it remains
poorly understood what adaptations may occur to FAO during
cancer progression.
HIF-1 was reported to regulate the expression of fatty acid
synthase (FASN) and lipin 1 (LPIN1) (Furuta et al., 2008; Mylonis
et al., 2012), which facilitate fatty acid synthesis (FAS) and lipid
storage, which are adaptive metabolic responses to hypoxia
(Menendez and Lupu, 2007). Hypoxia was also reported to
diminish FAO in cultured cardiac myocytes (Huss et al., 2001)
and in cardiac hypertrophy models in a HIF-1-dependent
manner (Krishnan et al., 2009). However, contradictory evidence
exists regarding the consequences of fatty acid catabolism, or
FAO, for cancer progression (Deberardinis et al., 2006; Zaugg
et al., 2011). Obviously, the beneficial role of FAO for cancer
growth may be context dependent, or cancer cell type specific,
and more extensive investigations are warranted to understand
the effect of cancer metabolic reprogramming on FAO.
In this study, we screened human hepatocellular carcinoma
(HCC) cells for genes encoding lipid metabolic enzymes that
are regulated by hypoxia through HIF-1. We report here a previ-
ously unappreciated mechanism by which HIF-1 suppresses the
medium-chain (MCAD) and long-chain (LCAD) acyl-CoA dehy-
drogenases and FAO to facilitate cancer progression by cross-
talk between metabolic and signal transduction pathways.RESULTS
Hypoxia Suppresses FAO in Cancer Cells in a HIF-1-
Dependent Manner
We first investigated if hypoxic stress regulates lipid metabolism
in human HCC cells. We cultured Hep3B, SK-Hep-1, and HepG2
cells under nonhypoxic (20% O2) or hypoxic (1% O2) conditionsthors
for 48 hr. Nile red staining and triglyceride (TG) measurement
in cell lysates revealed that hypoxic stress led to significant
lipid accumulation in all three cancer cell lines (Figures 1A and
1B). Because HIF-1 plays a major role in hypoxia-induced re-
programming of glucose metabolism in cancer cells, we next
explored whether HIFs are involved in the altered lipid meta-
bolism induced by hypoxic stress. We established Hep3B cells
stably expressing a nontargeting control (NTC) short hairpin
RNA (shRNA) or shRNA targeting HIF-1a, HIF-2a, or both (double
knockdown, DKD) (Figure 1C). Downregulation of HIF-1a or HIF-
2a or both attenuated hypoxia-induced lipid accumulation (Fig-
ures 1D and 1E), indicating that both HIF-1a and HIF-2a regulate
lipid metabolism in Hep3B cells.
To address the mechanisms underlying hypoxia-induced lipid
accumulation in cancer cells, we utilized a pathway-focused
PCR array of genes encoding lipid metabolic enzymes and
cDNA prepared from Hep3B cells that were cultured under non-
hypoxic or hypoxic conditions for 36 hr. Based on the PCR array
results, we designed primers and performed reverse transcrip-
tion and quantitative real-time PCR to confirm the expression
of genes that were hypoxia responsive in the array analysis. It
is intriguing that several major genes responsible for lipid syn-
thesis and lipid catabolism, or b-oxidation, were regulated by
hypoxia (Figure 1F). As reported (Furuta et al., 2008; Mylonis
et al., 2012), we observed hypoxia-induced expression of
several genes regulating lipid synthesis, including FASN and
LPIN1. Interestingly, several lipid catabolism genes, especially
MCAD and LCAD, were downregulated under hypoxic condi-
tions in Hep3B cells (Figure 1F), as well as in HepG2 and PC3
prostate cancer cells (Figures S1A and S1B). Because MCAD
and LCAD are key enzymes catabolizing the first step of FAO
inmitochondria, our observation that hypoxic stress dramatically
inhibits MCAD and LCAD expression suggests that FAO is sup-
pressed in hypoxic cancer cells, which might contribute to hyp-
oxia-induced lipid accumulation.
To test our hypothesis, we measured the FAO rate using
[1-14C]-palmitic acidor [1-14C]-oleic acid inHep3Bcells. Thecon-
version rate of palmitic acid or oleic acid into either acid-soluble
metabolites (ASM) or CO2 was measured under nonhypoxic and
hypoxic conditions, or in the presence of etomoxir, an FAO inhib-
itor. As expected, etomoxir decreased levels of ASM and CO2
produced from [1-14C]-palmitic acid in Hep3B cells (Figure 1G).
Interestingly, levels of ASM and CO2 produced from either
[1-14C]-palmitic acid (Figure 1G) or [1-14C]-oleic acid (Figure 1H)
are significantly inhibited in hypoxic Hep3B cells. Similar results
were observed in SK-Hep-1 (Figure S1C) and PC3 cells (Fig-
ure S1D), suggesting that hypoxic stress inhibits FAO in cancer
cells. Further studies using Hep3B cells that stably expressed
shRNAs targeting HIFs revealed that, in HIF-1a knockdown or
DKD cells, but not HIF-2a knockdown cells, hypoxia-induced in-
hibition of [1-14C]-palmitic acidor [1-14C]-oleic acidoxidationwas
attenuated (Figures 1I and1J), indicating thatHIF-1a, but notHIF-
2a, is required for inhibition of FAO in hypoxic Hep3B cells.
HIF-1a Suppresses FAO by Inhibiting the Expression of
MCAD and LCAD
We next asked whether MCAD and LCAD are key enzymes
responsible for HIF-1-mediated regulation of FAO and lipid re-Cell Reprogramming in cancer cells. MCAD and LCAD belong to the
acyl-CoA dehydrogenase family that also includes short-chain
(SCAD) and very-long-chain (VLCAD) acyl-CoA dehydrogenases
(Kunau et al., 1995). Among the family members, MCAD and
LCAD protein levels were significantly decreased under hypoxia
in all of the cell lines analyzed, including Hep3B, SK-Hep-1, and
HepG2 HCC cells, as well as PC3 prostate cancer and MCF-7
breast cancer cells (Figures 2A and S2A). Of note, hypoxia did
have some effects on the expression of CPT1A or CPT1C in
cell lines such as MCF-7, as previously reported (Zaugg et al.,
2011). However, we did not observe those effects in Hep3B cells
(Figures 2A and S2A). We thus focused on MCAD and LCAD for
further study.
Treatment of Hep3B cells with CoCl2 or desferrioxamine,
which are chemical inducers of HIF activity, also inhibited the
expression of MCAD and LCAD in a time-dependent manner
(Figure S2B). Knockdown of HIF-1a, but not HIF-2a, expression
attenuated the inhibitory effect of hypoxia on the expression of
MCAD and LCAD mRNA (Figure 2B) and protein (Figure 2C) in
Hep3B cells. Knockdown of HIF-1a expression in SK-Hep-1
or PC3 cells had the same effect (Figures S2C and S2D). More-
over, hypoxia failed to decrease MCAD and LCAD levels in HIF-
1a knockout mouse embryonic fibroblasts (KO-MEF) (Fig-
ure S2E), which provided further evidence that HIF-1a is critical
for hypoxia-induced downregulation of MCAD and LCAD
expression.
Next, we investigated the mechanism by which HIF-1a down-
regulates the expression of MCAD and LCAD, which catalyzes
the first step of FAO in mitochondria. Interestingly, we found
that hypoxia significantly decreased the expression of PGC-1b,
a transcription factor that plays critical roles in regulating mito-
chondrial function, in Hep3B cells as well as in HepG2 and
PC3 cells (Figures 2D and S2F). When PGC-1b expression was
knocked down, MCAD and LCADmRNA and protein expression
were significantly suppressed in Hep3B (Figures 2E and 2F)
and PC3 cells (Figures S2G and S2H), suggesting that PGC-1b
is directly involved in transcriptional regulation of MCAD and
LCAD, which is consistent with previous reports (Lin et al.,
2005; Espinoza et al., 2010). We have documented previously
that both HIF-1a and HIF-2a inhibit PGC-1b through c-Myc sup-
pression in VHL-null RCC4 renal carcinoma cells (Zhang et al.,
2007). Here, we found that hypoxic stress repressed c-Myc
and PGC-1b in Hep3B and PC3 cells (Figure S2I). Moreover,
western blot assays of Hep3B cells expressing HIF shRNAs re-
vealed that HIF-1a, but not HIF-2a, repressed c-Myc and
PGC-1b expression under hypoxia (Figure 2C), which is consis-
tent with our finding that HIF-1a, but not HIF-2a, downregulated
MCAD and LCAD expression under hypoxia. Moreover, down-
regulation of c-Myc by shRNA blocked the expression of PGC-
1b, MCAD, and LCAD, whereas forced expression of c-Myc
enhanced their expression in Hep3B cells (Figure S2J).
Decreased mRNA and protein levels of PGC-1b, MCAD, and
LCADwere also observed in c-Myc-depleted tetracycline-induc-
ible P493 cells (Figures S2K and S2L), further confirming that
c-Myc regulates expression of PGC-1b, which, in turn, regulates
the expression of MCAD and LCAD. Forced expression of c-Myc
counteracted the hypoxia-induced decrease of PGC-1b,
MCAD, and LCAD protein levels (Figure 2G), suggesting thatports 8, 1930–1942, September 25, 2014 ª2014 The Authors 1931
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Figure 1. Hypoxia Suppresses Fatty Acid Oxidation in Cancer Cells in a HIF-1-Dependent Manner
(A) Hep3B, SK-Hep-1 and HepG2 cells were incubated under normoxia or hypoxia for 48 hr, followed by staining with Nile Red and DAPI.
(B) Hep3B, SK-Hep-1, and HepG2 cells were cultured under normoxia or hypoxia for 48 hr. Cellular TG content was measured using the triglyceride detection kit.
The values were normalized to cellular protein.
(C) Western blot analysis of HIF-1a and HIF-2a in Hep3B cells stably expressing nontargeting control shRNA (NTC), HIF-1a shRNA (sh1a), HIF-2a shRNA (sh2a),
or HIF-1a shRNA plus HIF-2a shRNA (double knockdown, DKD) under normoxia or hypoxia for 4 hr.
(D and E) Hep3B cells stably expressing NTC, sh1a, sh2a, or DKD were treated under normoxia or hypoxia for 48 hr followed by Nile Red and DAPI staining (D) or
cellular TG measurement (E).
(legend continued on next page)
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HIF-1a-mediated suppression of the c-Myc/ PGC-1b axis is
involved in hypoxic regulation of MCAD and LCAD expression.
To investigate whether MCAD and LCAD are involved in HIF-
1a-regulated FAO suppression under hypoxia, Hep3B cells
were stably transfected with control pSIN-GFP vector or vector
encoding MCAD or LCAD or both (Figure 2J). FAO analysis using
[1-14C]-palmitic acid, [1-14C]-stearic acid, [1-14C]-oleic acid, or
[1-14C]-linoleic acid revealed that forced expression of MCAD
recovered hypoxia-inhibited ASM production from [1-14C]-pal-
mitic acid and [1-14C]-stearic acid (Figures 2H and S2M),
whereas LCAD overexpression recovered hypoxia-inhibited
ASM production from [1-14C]-oleic acid and [1-14C]-linoleic
acid (Figures 2I and S2N), providing evidence that MCAD and
LCAD are critical targets for hypoxia-induced repression of
FAO. Palmitic acid and stearic acid are saturated fatty acids,
whereas oleic acid and linoleic acid are unsaturated fatty acids.
Our results suggested that MCAD and LCAD may function in
saturated and unsaturated FAO, respectively. To confirm this hy-
pothesis, we generated Hep3B cells stably expressing control
shRNA, or shRNAs targeting MCAD, LCAD, or both (Figure 2M).
FAO analysis showed that MCAD knockdown primarily
repressed the palmitic acid and stearic acid oxidation rates (Fig-
ures 2K and S2O), whereas LCAD knockdown primarily inhibited
the oleic acid and linoleic acid oxidation rates (Figures 2L
and S2P), confirming our observation that MCAD and LCAD
mostly mediate saturated and unsaturated fatty acids oxidation,
respectively. It should be noted that LCAD knockdown appears
to slightly reduce saturated fatty acids oxidation, whereasMCAD
knockdown also reduces marginally unsaturated fatty acids
oxidation, but the effects are obviously not enough to attain
significance. Nile red staining and TG content measurements
showed that inhibition of MCAD or LCAD led to lipid accumula-
tion (Figures S2Q and S2R). Forced expression of both MCAD
and LCAD diminished the hypoxia-induced accumulation of lipid
and TGs in Hep3B cells (Figures S2S and S2T), suggesting that
both MCAD- and LCAD-dependent FAO contributed to the hyp-
oxia-induced lipid accumulation. It should be noted that forced
expression of either MCAD or LCAD alone only marginally
reduced hypoxia-induced lipid accumulation and TG content
elevation (Figures S2S and S2T), suggesting that inhibition of
both saturated and unsaturated FAO mediated by MCAD and
LCAD, respectively, is involved in elevated lipid accumulation
under hypoxic stress.
MCAD and LCAD Regulate Cell Proliferation in Part by
Altering ROS Levels
Because we have confirmed that MCAD and LCAD regulate lipid
metabolism in cancer cells, we next investigated the effect of
MCAD or LCAD on cancer cell proliferation. Our results revealed(F) Quantitative real-time PCR analyzed the mRNA expression of different enzym
hypoxia for 36 hr.
(G and H) Hep3B cells were cultured under normoxia or hypoxia for 48 hr in the pre
measured using the conversion rate of radiolabeled palmitic acid or oleic acid into
(I and J) Oxidation rates of [1-14C]-palmitic acid (I) or [1-14C]-oleic acid (J) weremea
normoxia or hypoxia for 48 hr, using the produced radioactive ASM and CO2.
b-actin serves as loading control in the western blot. Data were presented as me
compared to hypoxia-treated NTC group. See also Figure S1.
Cell Rethat MCAD- or LCAD-specific shRNA-stimulated cancer cell
growth compared to the nontargeting control shRNA (Figures
3A–3C). Moreover, cells expressing LCAD shRNA appeared to
have a greater growth advantage than those expressing MCAD
shRNA (Figures 3B and 3C). Similar results were observed in
Hep3B cells expressing another shRNA for MCAD or LCAD
(shMCAD-2 or shLCAD-2) (Figure S3A) and SK-Hep-1 cells
expressing MCAD or LCAD shRNA (Figures S3B and S3C), sug-
gesting that MCAD and especially LCAD possess tumor-sup-
pressive effects. However, forced expression of MCAD, LCAD,
or both in Hep3B cells showed no obvious effect on cell growth
under nonhypoxic conditions (Figure 3D), whereas, under
hypoxic conditions, forced expression of LCAD significantly in-
hibited cell growth as compared to GFP-expressing control
Hep3B cells (Figures 3E and 3F). Although overexpression of
MCAD did not inhibit cell growth (Figure S3D), simultaneous
expression of MCAD and LCAD manifested more potent inhibi-
tion of cell growth than LCAD alone under hypoxia (Figures 3E
and 3F).
In mitochondria, FAO generates acetyl-CoA, which enters the
TCA cycle to generate NADH, which donates electrons to the
electron transport chain (ETC) that eventually are used by com-
plex IV to reduce O2 to H2O. To investigate if MCAD and
LCAD affect cell proliferation by regulating cellular ROS levels,
ROS scavengers N-acetyl-cysteine (NAC, 5 mM) or glutathione
(GSH, 5 mM) were added to the culture media of Hep3B cells.
NAC or GSH eliminated the mild stimulating effect of MCAD
shRNA on cell proliferation (Figures 3B and 3C). Interestingly,
although NAC or GSH treatment partially reduced the difference
in proliferation between cells expressing shLCAD and those ex-
pressing NTC shRNA, cells expressing shLCAD still showed a
growth advantage, even in the presence of NAC or GSH (Figures
3B and 3C). Similar results were observed in SK-Hep-1 cells (Fig-
ure S3C). Under hypoxic conditions, NAC or GSH also partially
rescued the growth inhibition caused by forced expression of
LCAD (Figures 3E and 3F). Cellular ROS measurement by di-
chlorofluorescein (DCF) staining and flow cytometry revealed
reduced ROS levels in MCAD or LCAD knockdown cells as
compared to the control group in Hep3B cells (Figures 3G, 3H,
and S3E) as well as in SK-Hep-1 cells (Figures S3F and S3G).
Overexpression of MCAD, LCAD, or both did not lead to signifi-
cant changes in ROS levels under nonhypoxic conditions (Fig-
ure 3I). However, under hypoxia, ROS levels were significantly
increased in MCAD- or LCAD-overexpressing cells, as well as
in cells with coexpression of MCAD and LCAD (Figure 3J). Treat-
ment with etomoxir decreased ROS levels in Hep3B cells (Fig-
ure S3E). Taken together, these data indicate that inhibition of
MCAD and LCAD diminished cellular ROS levels by modulating
FAO and mitochondrial respiration. MCAD and LCAD modulatees involved in fatty acid metabolism in Hep3B cells treated under normoxia or
sence of [1-14C]-palmitic acid (G) or [1-14C]-oleic acid (H). Oxidation rates were
either ASM or CO2. Etomoxir (eto) (100 mM) was used as a positive control (G).
sured in Hep3B cells stably expressing NTC, sh1a, sh2a, or DKD treated under
an (±SD). *p < 0.05 as compared to corresponding control group; #p < 0.05 as
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Figure 2. HIF-1a Suppresses Fatty Acid Oxidation by Inhibiting the Expression of MCAD and LCAD
(A) Western blot analysis of the proteins associated with FAO in Hep3B cells cultured under normoxia or hypoxia for 24 and 48 hr.
(B) Quantitative real-time PCR analysis of MCAD and LCAD mRNA expression in Hep3B cells stably expressing NTC, sh1a, sh2a, or DKD cultured under
normoxia or hypoxia for 24 hr.
(C) Hep3B cells stably expressing NTC, sh1a, sh2a, or DKD were cultured under normoxia or hypoxia for 48 hr, followed by western blot analyzing protein
expression of MCAD, LCAD, c-Myc, and PGC-1b.
(legend continued on next page)
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Figure 3. MCAD and LCAD Regulate Cell
Proliferation in Part by Altering ROS in Can-
cer Cells
(A) Western blot analysis of MCAD and LCAD in
Hep3B cells stably expressing NTC, shMCAD, or
shLCAD.
(B and C) Cell growth curves of Hep3B cells stably
expressing NTC, shMCAD, or shLCAD in the
absence or presence of 5 mM NAC (B) or GSH (C)
were determined by trypan blue counting.
(D) Cell growth curves of Hep3B cells stably ex-
pressing GFP, MCAD, LCAD, or M+L under nor-
moxia were determined by trypan blue counting.
(E and F) Cell growth curves of Hep3B cells stably
expressing GFP, LCAD, or M+L under hypoxia
with or without 5 mM NAC (E) or GSH (F) were
determined by trypan blue counting.
(G and H) ROS levels were measured by flow cy-
tometry in Hep3B cells stably expressing NTC,
shMCAD (G), or shLCAD (H) using the DCF fluo-
rescence.
(I and J) ROS levels were measured by flow cy-
tometry in Hep3B cells stably expressing GFP,
MCAD, LCAD, or both (M+L) under normoxia (I) or
hypoxia (J) using deep red fluorescence.
Data were presented as mean (±SD). *p < 0.05 as
compared to corresponding control group. See
also Figure S3.cell proliferation in part by regulating ROS production. Cells
overexpressing LCAD showed a significant growth disadvan-
tage, even in the presence of NAC, suggesting that other mech-
anisms beyond ROS might be involved in the regulation of cell
proliferation by LCAD.
To explore whether MCAD and LCAD regulate energy homeo-
stasis, we measured ATP in Hep3B cells. Knockdown of MCAD
or LCAD expression had no effect on cellular ATP levels under
either normal or glutamine-free culture conditions (Figures S3H
and S3I). However, ATP levels were significantly decreased in
MCAD or LCAD knockdown Hep3B cells under glucose-free
conditions (Figures S3H and S3I), suggesting that FAO could
become a major source of ATP production in cancer cells in
the absence of glucose. Consistent with this observation,(D) Hep3B cells were cultured under normoxia or hypoxia for 24 hr, followed by quantitative real-time PCR an
PPRC1, PPARa, PPARd and PPARg.
(E and F) mRNA (E) and protein (F) expression of PGC-1b, MCAD, and LCADwere measured in Hep3B cells st
(G) Hep3B cells with stable expression of pMX empty vector (EV) or pMX-c-Myc were treated under normoxia
PGC-1b, MCAD, and LCAD.
(H and I) Conversion of [1-14C]-palmitic acid (H) or [1-14C]-oleic acid (I) into ASM was measured in Hep3B c
MCAD and LCAD cultured under normoxia or hypoxia for 48 hr.
(J) Protein expression of endogenous and exogenous MCAD and LCAD were analyzed in Hep3B cells stably
LCAD cultured under normoxia or hypoxia for 48 hr.
(K and L) Conversion of [1-14C]-palmitic acid (K) or [1-14C]-oleic acid (L) into radioactive ASM or CO2 was mea
shRNA (shLCAD), MCAD shRNA (shMCAD), or MCAD shRNA plus LCAD shRNA (shM+shL).
(M) Western blot analysis of MCAD and LCAD protein in Hep3B cells stably expressing NTC, shMCAD, shL
b-actin serves as loading control in the western blot. Data were presented as mean (±SD). *p < 0.05 as co
Figure S2.
Cell Reports 8, 1930–1942, Sepwhen FAO was inhibited by etomoxir, or
repressed by loss of function of MCAD
and LCAD, glucose uptake and lactateproduction increased (Figures S3J and S3K), indicating that
glycolytic metabolism in cancer cells is enhanced when FAO is
inhibited. Conversely, accelerating FAO by co-overexpressing
MCAD and LCAD attenuated hypoxia-induced glucose uptake
and lactate production (Figures S3L and S3M), indicating that
augmenting FAO inhibits glycolytic metabolism in cancer cells.
Hypoxia induces increased glucose uptake and lactate produc-
tion by upregulating expression of glycolytic genes, such as
glucose transporter 1 (GLUT1) and lactate dehydrogenase A
(LDHA). However, neither MCAD nor LCAD regulates expression
of GLUT1 or LDHA (Figure S3N; data not shown). Instead, mRNA
and protein expression of glucose transporter 2 (GLUT2) were
significantly increased in Hep3B cells expressing shRNA target-
ing MCAD or LCAD (Figures S3N and S3O), suggesting thatalyzing the mRNA expression of PGC-1a, PGC-1b,
ably expressing NTC or shRNAs targeting PGC-1b.
or hypoxia for 48 hr, followed by protein analysis of
ells stably expressing GFP, MCAD, LCAD, or both
expressing GFP, MCAD, LCAD, or both MCAD and
sured in Hep3B cells stably expressing NTC, LCAD
CAD, or shM+shL.
mpared to corresponding control group. See also
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Figure 4. Depletion of LCAD Promotes Can-
cer Cell Proliferation by Reducing PTEN
(A and B) Quantitative real-time PCR analysis of
PTEN mRNA expression (A) and western blot
analysis of MCAD, LCAD, PTEN, serine 473
phosphorylation AKT (p-AKT), and AKT levels (B)
were performed in Hep3B cells stably expressing
NTC, shMCAD, shLCAD, or shM+shL.
(C and D) Hep3B cells stably expressing NTC,
shLCAD, or shM+shL were further infected with
viruses expressing pBABE EV or pBABE-PTEN.
PTEN protein levels (C) and cell growth curve was
determined (D).
(E) PTEN, p-AKT, and AKT levels were determined
by western blot in Hep3B cells stably expressing
GFP, MCAD, LCAD, or M+L under normoxia or
hypoxia for 48 hr.
(F) Hep3B cells stably expressing GFP, MCAD,
LCAD, or both MCAD and LCAD were further in-
fected with viruses expressing NTC or PTEN
shRNA (shPTEN) or cultured in the presence of
50 mM oleic acid (OA) or palmitic acid (PA). PTEN,
p-AKT, and AKT levels were determined by west-
ern blot in those cells treated under hypoxic con-
dition for 48 hr.
(G) Hep3B cells stably expressing GFP or LCAD
were further infected with viruses expressing NTC
or shPTEN, followed by cell growth curve analysis
by trypan blue counting under hypoxic condition.
(H) Cell growth curves of Hep3B cells stably ex-
pressing GFP or LCAD in the presence or absence
of 50 mM OA under hypoxic condition were
determined by trypan blue counting.
b-actin serves as loading control in the western
blot. Data were presented as mean (±SD). *p <
0.05 as compared to corresponding control group;
NS, not significant. See also Figure S4MCAD and LCAD may affect glucose uptake and glycolytic
metabolism by regulating GLUT2 expression. Nevertheless,
although our data demonstrating regulation of GLUT2 by
MCAD and LCAD might provide a feedback mechanism for
enhanced glucose uptake for ATP production when FAO is sup-
pressed, unfortunately, it could not explain the differential effect
of MCAD versus LCAD on cancer cell proliferation.
Depletion of LCAD Promotes Progression of Cancer
Cells by Reduction of PTEN
The differential effect between MCAD and LCAD on cancer cell
proliferation led us to search further for other mechanisms
beyond ROS and ATP. Our data indicated that MCAD primarily
mediates oxidation of palmitic acid (C16:0) and stearic acid
(C18:0) (Figures 2H, 2K, S2M, and S2O), whereas LCAD medi-
ates oxidation of oleic acid (C18:1) and linoleic acid (C18:2) (Fig-
ures 2I, 2L, S2N, and S2P). It has been reported that unsaturated1936 Cell Reports 8, 1930–1942, September 25, 2014 ª2014 The Authorsfatty acids, including oleic acid and lino-
leic acid, facilitate cell proliferation by
inhibiting transcription of the PTEN tu-
mor suppressor gene in HCC (Vinciguerra
et al., 2009). Knockdown of LCAD, but not
MCAD, significantly decreased PTENmRNA and protein expression in Hep3B cells (Figures 4A and
4B). Phosphorylation of serine 473 (S473) on AKT was signifi-
cantly enhanced by knockdown of LCAD, but only marginally
increased by MCAD knockdown (Figure 4B), indicating that
AKT was activated by PTEN repression in cells with LCAD loss
of function. To further address if PTEN is involved in LCAD-regu-
lated cancer cell proliferation, we overexpressed PTEN in LCAD
knockdown cells, which have low levels of endogenous PTEN
(Figure 4C). Forced expression of PTEN diminished the growth
advantage of LCAD knockdown cells (Figure 4D), demonstrating
that PTEN repression is required for increased proliferation in
cells with loss of LCAD expression.
Because hypoxic stress inhibits LCAD expression and induces
accumulation of lipids (including both saturated and unsaturated
fatty acids), we next analyzed PTEN expression and AKT activa-
tion under hypoxic stress. The results showed that hypoxia leads
to suppression of PTEN expression and activation of AKT S473
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Figure 5. LCAD Suppresses Tumor Growth
in Vivo
(A and B) Hep3B cells stably expressing NTC,
shMCAD, or shLCAD were injected subcutane-
ously into nude mice (n = 5 for each group). Tumor
growth curves were measured starting from
10 days after inoculation (A), and tumors were
extracted and compared at the end of the experi-
ment (B).
(C) Protein levels of MCAD, LCAD, PTEN, p-AKT,
and AKT were determined by western blot using
the lysates from four independent tumors of each
group as in (B).
(D) Representative imaging of oil red O staining
using the frozen sections of extracted tumors from
different groups as in (B) was shown.
(E) TG concentrations in the lysates from extracted
tumors in (B) were measured by triglyceride
detection kit, and the values were normalized to
protein.
(F and G) Hep3B cells stably expressing GFP,
MCAD, LCAD, or M+L were injected subcutane-
ously into nude mice (n = 5 for each group). Tumor
growth curves were measured starting from
10 days after inoculation (F), and tumors were
extracted and compared at the end of the experi-
ment (G).
(H) Protein levels of endogenous and exogenous
MCAD and LCAD, PTEN, p-AKT, and AKT were
determined by western blot using the lysates from
three independent tumors of each group as in (G).
(I) Representative imaging of oil red O staining
using the frozen sections of extracted tumors from
different groups as in (G) was shown.
(J) TG concentrations in the lysates from extracted
tumors in (G) were measured by triglyceride
detection kit, and the values were normalized to
protein.
b-actin serves as loading control in the western
blot. Data were presented as mean (±SD). *p <
0.05 as compared to corresponding control group;
NS, not significant. See also Figure S5.phosphorylation, which were reversed by forced expression of
LCAD (Figure 4E). To further confirm that the PTEN pathway is
involved in LCAD-induced inhibition of cell proliferation, we
knocked down PTEN in LCAD-overexpressing Hep3B cells (Fig-
ure 4F). Western blot results demonstrated that downregulation
of PTEN counteracted the inhibitory effect of LCAD on AKT
phosphorylation under hypoxic conditions (Figure 4F). More
importantly, knocking down PTEN diminished the inhibitory ef-
fect of LCAD on cell proliferation under hypoxic stress (Fig-
ure 4G), further demonstrating that PTEN is required for the
regulation of cell proliferation by LCAD. Addition of oleic acid,
but not palmitic acid, into cell-culture media inhibited PTEN
expression and enhanced S473 phosphorylation of AKT in
hypoxic Hep3B cells (Figure 4F). Addition of oleic acid also
counteracted the inhibitory effect of LCAD on cell proliferation
(Figure 4H), suggesting that decreased oleic acid levels are
responsible for cell growth inhibition in cells with LCAD overex-
pression. Because oleic acid and palmitic acid differ both withCell Rerespect to saturation and carbon chain length, we designed ex-
periments to determine whether saturation or chain length of
fatty acids affects PTEN expression and cell growth. Both west-
ern blot and cell growth curves showed that only unsaturated
fatty acids such as oleic acid (C18:1) and palmitoleic acid
(C16:1), but not saturated stearic acid (C18:0) or palmitic acid
(16:0), inhibited PTEN expression and stimulated cell growth in
Hep3B cells (Figures S4A and S4B). Taken together, our results
indicate that, besides ROS, LCAD, but not MCAD, also inhibits
cell proliferation under hypoxia via enhanced PTEN expression.
LCAD Suppresses Tumor Growth In Vivo
Analysis of mouse xenografts using Hep3B cells that stably ex-
pressed shRNA targeting LCAD or MCAD showed that knock-
down of LCAD, but not MCAD, significantly enhanced tumor
volume (Figures 5A and 5B) and mass (Figure S5A) as compared
to the nontargeting control group. Consistent with the in vitro
data, lysates from tumor tissues revealed that tumors generatedports 8, 1930–1942, September 25, 2014 ª2014 The Authors 1937
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Figure 6. LCAD Deficiency Correlates with
Human HCC and Predicts Poor Clinical
Prognosis
(A) mRNA expressions of SCAD, MCAD, LCAD,
and VLCAD were determined by quantitative real-
time PCR in 20 pairs of clinically matched tumor
adjacent noncancerous liver tissues (normal) and
human HCC tissues (tumor). mRNA levels were
normalized to 18S.
(B) HIF-1a, PGC-1b, LCAD, PTEN, and p-AKT
were determined by western blot using the paired
tumor adjacent noncancerous liver tissues and
human HCC tissues.
(C) Representative IHC analysis of LCAD expres-
sion in normal liver tissues (normal) and HCC
specimens of different clinical stages (I–IV) was
shown.
(D) Statistical quantification of the mean optical
density (MOD) values of LCAD staining in IHC
assay between normal liver tissues and HCC
specimens of different clinical stages (I–IV). The
MOD of LCAD staining decreases as HCC pro-
gresses to a higher clinical stage.
(E) Kaplan-Meier curves with univariate analyses
for patients with low versus high LCAD expression.
b-actin serves as loading control in the western
blot. Data were presented as mean (±SD). *p <
0.05 as compared to corresponding control group;
NS, not significant. See also Tables S1–S4.from LCAD knockdown cells, but not those of MCAD knockdown
cells, had lower PTEN expression and elevated phosphorylation
of AKT at S473 (Figure 5C). On the other hand, forced expression
of LCAD, but not MCAD, markedly reduced tumor volume
(Figures 5F and 5G) and mass (Figure S5B), indicating that
LCAD, but not MCAD, is critical for regulation of tumor growth.
Enhanced PTEN expression and reduced AKT phosphorylation
were observed in tumors generated from LCAD-overexpressing
cells (Figure 5H). Oil red O staining of frozen sections and
TG content measurement in tissue lysates revealed that downre-
gulation of MCAD- or LCAD-stimulated lipid accumulation (Fig-
ures 5D and 5E), whereas overexpression of MCAD or LCAD
decreased lipid storage compared to the control group (Figures
5I and 5J), which are consistent with data from in vitro experi-
ments. Also, these data are consistent with previously reports
that MCAD- or LCAD-deficient mice have abnormal lipid accu-
mulation in the liver (Kurtz et al., 1998; Tolwani et al., 2005).1938 Cell Reports 8, 1930–1942, September 25, 2014 ª2014 The AuthorsDecreased LCAD Expression in
HCC Predicts Patient Mortality
Analysis of cell proliferation in vitro and
tumor growth in vivo indicated that
LCAD has a tumor-suppressive effect.
To investigate the physiological signifi-
cance of this regulatory pathway, LCAD
expression was also studied in 20 paired
HCC lesions and adjacent noncancerous
tissue samples. Among the acyl-CoA de-
hydrogenases, only LCAD mRNA levels
were significantly decreased in HCC le-
sions as compared to adjacent normaltissue (Figure 6A). Although MCAD expression is decreased by
hypoxic stress in cultured cells, we did not observe any signifi-
cant difference in mRNA expression between HCC lesions and
adjacent normal tissue (Figure 6A). Further, western blot assays
showed decreased PGC-1b, LCAD, PTEN protein levels and
enhanced HIF-1a and AKT phosphorylation levels in HCC tissue
as compared to adjacent normal tissue (Figure 6B).
Next, immunohistochemistry (IHC) was employed to analyze
LCAD expression in a retrospective cohort of 158 clinicopatho-
logically characterized HCC cases, including ten cases of stage
I (6.3%), 106 cases of stage II (67.1%), 33 cases of stage III
(20.9%), and nine cases of stage IV (5.7%) liver cancer, based
on the TNM staging (Table S1). IHC results revealed that LCAD
protein was abundantly expressed in normal liver, weakly ex-
pressed in early-stage HCC (TNM stages I and II) and barely
detectable in late-stage HCC (TNM stages III and IV) (Figure 6C).
Image analysis of the IHC revealed that LCAD expression in
Figure 7. HIF-1-Mediated Suppression of Fatty Acid Oxidation Is
Critical for Cancer Progression
HIF-1 has been well defined to facilitate glycolysis under hypoxic stress in
cancer cells. Here, we depict that HIF-1a inhibits b-oxidation by repressing the
expression of MCAD and LCAD (in green), two family members of acyl-CoA
dehydrogenases that catalyze the first step of b-oxidation in mitochondria.
Both MCAD- and LCAD-regulated fatty acid oxidation facilitates tumor cell
proliferation by altering ROS levels and glycolysis. However, deficiency of
LCAD-induced unsaturated fatty acid oxidation possesses the most potent
effect on cancer progression by regulating the PTEN pathway. See text for
details.clinical stage I–IV primary tumors was significantly decreased
compared to normal liver (Figure 6D). Furthermore, LCAD was
drastically downregulated in late-stage HCC (stages III and IV)
as compared to early-stage HCC (stages I and II) (Figure 6D;
Table S2), suggesting that LCAD expression was gradually
decreased as HCC progressed to a higher clinical stage. Further,
Spearman analysis revealed correlations between LCAD expres-
sion and patient clinicopathological characteristics, including
survival time, vital status, clinical stage, and tumor size (Table
S3), further suggesting a strong association of LCAD expression
with HCCclinical staging and patient survival. Univariate analysis
revealed that, together with TNM stage and tumor size, LCAD
level is a significant prognostic factor. Multivariate analysis
also demonstrated that LCAD expression and clinical TNM stag-
ing are predictive of the overall survival of HCC patients (Table
S4). Finally, Kaplan-Meier test indicated that LCAD expression
in HCC patients was significantly associated with survival time,
with patients expressing high LCAD in their HCC lesions surviv-
ing much longer than those with low LCAD expression (Fig-
ure 6E), suggesting that LCADproteinmay represent a promising
prognostic biomarker in HCC.
DISCUSSION
There is a growing appreciation that cancer cells generally un-
dergo comprehensive metabolic reprogramming, which gener-
ally permits rapid growth and allow adaptation to the tumorCell Remicroenvironment (DeBerardinis et al., 2008). HIFs have been
intensively investigated for their roles in metabolic reprogram-
ming (Semenza, 2010). Nevertheless, whereas hypoxia- and
HIF-dependent regulation of glycolysis, glutaminolysis, and lipid
synthesis have been demonstrated (Kim et al., 2006; Furuta
et al., 2008; Metallo et al., 2012), the effect of hypoxia and
HIFs on FAO in cancer cells had not been clearly elucidated. In
this regard, it is significant that we establish here a previously un-
appreciated mechanism by which HIF-1 suppresses acyl-CoA
dehydrogenases and FAO in hypoxic cells to facilitate cancer
progression. It is intriguing to note that, whereas we observed
similar roles for both HIF-1 and HIF-2 in causing lipid accumula-
tion in hypoxic cancer cells (Figures 1D and 1E), only HIF-1 sup-
presses expression of acyl-CoA dehydrogenases and FAO (Fig-
ures 1I, 1J, and 2C), highlighting overlapping but differential roles
for HIF-1 and HIF-2 in regulating lipidmetabolism of cancer cells.
It has been documented recently that lipid synthesis is regu-
lated by hypoxia stress in cancer cells (Anastasiou and Cantley,
2012). We also observed the enhanced expression of genes for
FAS in HCC cells (Figure 1F). Proliferating cancer cells require
lipid for cellular membrane synthesis and other essential func-
tions. Cancer cells generally adopt a de novo lipid synthesis
strategy rather than use of stored lipids, and, as a result, accu-
mulation of lipid droplets is commonly observed in cancer cells
(Kuhajda, 2000). Hence, one would expect reduced lipid catab-
olism in cancer cells to sustain rapid cell proliferation. Neverthe-
less, recent results from several groups did not seem to be in
agreement with this expectation. In contrast, prosurvival roles
have been reported for FAO under various conditions (Deberar-
dinis et al., 2006; Zaugg et al., 2011). It is interesting that we
demonstrate that, whereas enhanced FAO under normoxic con-
ditions does not affect cancer cell growth, it is detrimental under
hypoxia. Hence, we assume that previous observations of FAO
as beneficial for cancer proliferation may be context dependent
or cancer cell type specific, as demonstrated by different conse-
quences of FAO alteration reported by different groups (Deberar-
dinis et al., 2006; Zaugg et al., 2011). Importantly, at least in the
multiple cancer cell lines studied here, we provide clear evidence
showing that HIF-1a-mediated suppression of FAO is beneficial
for cancer proliferation via reduced ROS production, enhanced
Glut2 expression and glycolysis, and activation of prosurvival
cancer signaling (Figure 7).
It was surprising that the expression of LCAD but not MCAD
was suppressive to cancer growth. LCAD and MCAD both
catabolize the first step of FAO in mitochondria but differ, ac-
cording to the original definitions, in the chain length of their fatty
acid substrates. Nevertheless, LCAD is also known to mediate
unsaturated fatty acid oxidation, whereas MCAD prefers satu-
rated fatty acids as substrates. As a result, only loss of LCAD,
but not MCAD, will lead to accumulation of unsaturated fatty
acids. Kidwell et al. reported the requirements of unsaturated
fatty acids for growth and survival of a rat mammary tumor cell
line (Kidwell et al., 1978). Animals fed a diet high in unsaturated
fatty acidswere found to bemore susceptible to cancer develop-
ment (Bartsch et al., 1999). Unsaturated fatty acids inhibit PTEN
via miR-21 upregulation in hepatocytes (Vinciguerra et al., 2009).
This led us to hypothesize that loss of LCAD, but not MCAD,
led to accumulation of unsaturated fatty acids, which, in turn,ports 8, 1930–1942, September 25, 2014 ª2014 The Authors 1939
suppress PTEN, resulting in cancer progression. Indeed, our re-
sults confirmed that only the unsaturated fatty acids oleic acid
and palmitoleic acid blunted PTEN expression in cultured cells
(Figure S4A). Importantly, our in vivo results from mouse tumor
xenograft models demonstrated that loss of LCAD, but not
MCAD, resulted in suppression of PTEN in vivo and enhanced
tumor growth (Figures 5A–5C). Our discovery establishes a
mechanism by which reprogrammed lipid metabolism in cancer
cells promotes proliferation by crosstalk with signal transduction
pathways.
Accumulating clinical evidence suggests that lipid disorders
are correlated with cancer incidence. Calle et al. reported that
up to 20% of all deaths from cancer are related to obesity (Calle
et al., 2003). In fact, alterations of many metabolism-related
genes, such as IDH1, IDH2, FH, SDH, and PKM2, have been
identified to cause human malignancies (Thompson, 2009).
Hence, it is very interesting to observe that decreased expres-
sion of LCAD led to suppression of PTEN, whose deletion or
diminished expression in HCC was associated with a poor prog-
nosis (Vinciguerra and Foti, 2008), suggesting a suppressive role
for LCAD in human malignancies. Among the family members of
acyl-CoA dehydrogenase, whereas SCAD, MCAD, and VLCAD
are implicated in human inherited disorders of fatty acid oxida-
tion (Lea et al., 2000), there is no similar report involving LCAD
in any human diseases, at least to the best of our knowledge.
Of note, a thorough search and analysis of publicly available
data sets led us to the discovery of one oncomine data set
(Data Link: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE14520), in which the expression of LCAD was compre-
hensively suppressed in human liver cancers (Roessler et al.,
2010). However, those alterations had never been specifically
studied. In this regard, it is very interesting that, besides results
from cancer cell lines and mouse tumor models to demonstrate
the role of HIF-1-mediated suppression of LCAD in cancer pro-
gression, we identified in 158 clinical HCC samples that loss of
LCAD is correlated with poor clinical prognosis of HCC. Hence,
our discovery in this study is highly relevant to human cancers.
Although further endeavors are under way to determine whether
alterations in LCAD expression and activity in hepatocytes are
reliable prognostic markers for HCC, it is safe to predict that
understanding the molecular mechanisms regulating lipid meta-
bolism in cancer cells and their connection to activated signal
transduction pathways that promote cancer cell proliferation
and survival will provide opportunities to design novel therapeu-
tic strategies to harness human malignancies.EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
Human 293T, Hep3B, HepG2, SK-Hep-1, MCF-7, and RCC4 cells were
cultured in Dulbecco’s modified essential medium (DMEM). PC3 and P493
cells were cultured in RPMI-1640. The media were supplemented with 10%
FBS and 1% penicillin-streptomycin. Mouse embryo fibroblasts (MEFs) were
cultured in DMEM with 15% FBS, 2 mM sodium pyruvate, nonessential amino
acids, and 1% penicillin-streptomycin.
Plasmids and Establishing Stable Cells
shRNAs targeting HIF-1a or HIF-2a were inserted into pRPL-GFP-Puro vector
as previously reported (Zhang et al., 2012). shRNAs targeting MCAD, LCAD,1940 Cell Reports 8, 1930–1942, September 25, 2014 ª2014 The Auc-Myc, PGC-1b, or PTEN were purchased from Sigma-Aldrich. Expression
vector pMX-c-Myc was purchased from Addgene (Plasmid 17220). CDS
sequence of humanMCAD or LCADwas inserted into pSIN-GFP lentiviral vec-
tor at BamHI and SpeIsites. CDS sequence of human PTEN was inserted into
pBABE lentiviral vector at BamHI and EcoRI sites. Transduction and viral infec-
tion was performed as previously described (Zhang et al., 2007).
Nile Red Staining and Triglyceride Measurement
To visualize lipid droplets, cultured cells were fixed with 4% paraformaldehyde
and then stained with 0.05 mg/ml Nile red (19123; Sigma-Aldrich) for 10 min
followed by PBS washing and DAPI staining. Imagings were visualized by
immunofluorescence microscopy. For triglyceride measurement, cells were
collected and lysed with RIPA buffer supplied with 1%NP-40 for 30min, equal
volume of cell lysates were used to measure triglyceride using a Biochemical
Triglyceride Determination Kit (F001-2; NJJC Bio). The triglyceride values were
normalized to cellular protein measured with Bradford Protein Assay Kit
(SK3031; Sangon Bio).
Fatty Acid b-Oxidation
For measurement of palmitic acid, stearic acid, oleic acid, or linoleic acid
oxidation, cells were incubated at 37C in DMEM supplied with 1 mCi/ml
[1-14C]-palmitic acid, [1-14C]-stearic acid, [1-14C]-oleic acid, or [1-14C]-linoleic
acid (PerkinElmer Life and Analytical Sciences), 1 mM nonradioactive palmitic
acid, stearic acid, oleic acid, or linoleic acid, 10 mM HEPES, and 0.5% fatty
acid free BSA (Sigma-Aldrich), as previous reported (Kim et al., 2000).
Produced 14CO2 on the filter paper and
14C-ASM in the supernatant were
determined by scintillation counting (PerkinElmer; Tri-Carb). Values were
normalized to protein quantification of cell lysate.
Western Blot
Cells were lysated with RIPA buffer and equal amounts of protein in the lysates
were boiled and fractionated by 7%–10% SDS-PAGE. Primary antibodies
against the following proteins were used: HIF-1a (BD Bioscience); HIF-2a,
c-Myc, and PGC-1b (Santa Cruz Biotechnology); b-actin, a-tubulin (Abmart);
SCAD, MCAD, LCAD, VLCAD, ACSL1, CPT1A, CPT1C, GLUT1, and GLUT3
(Proteintech); GLUT2 (Millipore); PTEN (Cascade); VDAC, AKT, and p-AKT
(ser 473) (CST). Horseradish-peroxidase-conjugated anti-rabbit and anti-
mouse (Bio-Rad) secondary antibodies were used. Signal was detected using
Western ECL Substrate (Bio-Rad).
Quantitative Real-Time PCR
Primer sequences were showed in Table S5, quantitative real-time PCR was
performed using iScript SYBR Green PCR Kit (Bio-Rad) on a Bio-Rad iCycler.
Animal Studies
All animal studies were conducted with approval from the Animal Research
Ethics Committee of the University of Science and Technology of China. For
xenograft experiments, different Hep3B cell lines were injected subcutane-
ously into nude mice (SJA Laboratory Animal Company). Ten days after injec-
tion, tumor volumes were measured every 3 days with a caliper and calculated
using the equation, volume = width * depth * length * 0.52.
Oil Red O Staining
Frozen sections from mice subcutaneous tumors were fixed in 10% formalin,
washed with 60% propylene glycerol, and then stained with 0.5% oil red O
(Sangon Bio) in propylene glycerol for 10 min at 60C. The red lipid droplets
were visualized by microscopy.
Clinical Human Tissue Specimen
The normal liver tissues were collected from patients undergoing resection of
hepatic hemangiomas at the Department of Hepatobiliary Surgery, the First
Affiliated Hospital of Sun Yat-sen University. Formalin-fixed, paraffin-
embedded primary HCC specimens obtained from 158 patients were
randomly selected from the archives of the Sun Yat-sen University Cancer
Center (Guangzhou, China). The 20 paired HCC lesions and the adjacent
noncancerous clinical tissue samples were collected from HCC patients. For
use of these clinical materials for research purposes, prior patients’ writtenthors
informed consents and approval from the Institutional Research Ethics Com-
mittee of Sun Yat-sen University Cancer Center were obtained. Tumor clinical
stages were defined according to the 2002 American Joint Committee on Can-
cer/International Union against Cancer tumor/lymph node metastasis/distal
metastasis (TNM) classification system.
Statistical Analysis
The relationship between LCAD expression and clinicopathological character-
istics was analyzed by the chi-square test. Survival curves were plotted by
the Kaplan-Meier method and compared using the log-rank test. Data are
presented as the mean (±SD) of at least three independent experiments. Sta-
tistical significance (p < 0.05) was assessed by the Student’s t test unless
otherwise noted.
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